Earlier this year, Intuitive Surgical warned that supplies may be tight in the months ahead as it continues to roll out the ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder in a ...

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recogni | In ...

Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

It’s been a whirlwind year for Joerg Moeller, M.D. After being appointed CEO of BenevolentAI in January, Moeller is now out ...

Roche has made another MAGE-A4 program disappear, withdrawing a phase 1 trial of a T-cell bispecific prospect before a single ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

Just as Smita Gopinath, Ph.D., was setting up her microbiology and immunology lab at Harvard T.H. Chan School of Public ...